Monthly Update Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Current perspectives on disease activity markers for rheumatoid arthritis

References

• HARRIS ED: Rheumatoid arthritis. Pathophysiology andImplications for therapy. New Engl. J. Med. (1990) 322:1277–1289.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ANDERSON jj, BOERS M et al.: The AmericanCollege of Rheumatology preliminary core set of dis-ease activity measures for rheumatoid arthritis trials. Arthritis Rheum. (1993) 36:729–740.
   PubMed Web of Science ®Google Scholar
• LUQMANI RA, SHEERAN TP, WINKLES J et al.: Cytolcinesand the acute phase response in rheumatoid arthritis. Br. J. Rheumatol. (1991) 30(Suppl.):6.
   Google Scholar
• DAWES PT, FOWLER PD, CLARKE S et al.: Rheumatoid arthritis: treatment which controls the C-reactive pro-tein and erythrocyte sedimentation rate reduces radi-ologk progression. Br. J. Rheumatol. (1986) 25:44–49.
   PubMedGoogle Scholar
• EDMONDS JP, SCOOT DL, FURST DE, BROOKS P, PAULUS HE: Antirheumatic drugs: a proposed new classifica-tion. Arthritis Rheum. (1993) 36:336–339.
   PubMed Web of Science ®Google Scholar
• SHARP JT, LIDSKY MD, COLLINS LC, MORELAND J: Meth-ods of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis Rheum. (1971) 14:706–720.
   PubMed Web of Science ®Google Scholar
• LARSEN A, DALE K, EEK M: Radiographic evaluation of rheumatoid arthritis and related conditions by stand-ard reference films. Acta Radiologica Diagn. (1977) 18:481–491.
   PubMed Web of Science ®Google Scholar
• POOLE AR, DIEPPE P: Biological markers in rheumatoid arthritis. Sem. Arthritis Rheum. (1994) 23\(Suppl. 2):17–31.
   Google Scholar
• SAXNE T, HEINEGARD D: Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum. (1992) 35 :385–390.
   PubMed Web of Science ®Google Scholar
• POOLE AR, IONESCU M, SWAN A, DIEPPE PA: Changes incartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteo-glycan aggrecan. Implications for pathogenesis.. J. Clin. Invest. (1994) 94:25–33.
   PubMed Web of Science ®Google Scholar
• MANSSON B, CAREY D, ALINI M et al.: Cartilage and bonemetabolism in rheumatotid arthritis. Differences be-tween rapid and slow progression of disease identified by serum markers of cartilage metabolism. J. Clin. Invest. (1995) 95:1071–1077.
   Google Scholar
• PITSILLIDES AA, WORRALL JG, WILKINSON LS, BAYLISSMT, EDWARDS JCW: Hyaluronan concentration in non-inflamed and rheumatoid synovium. J. Rheumatol. (1994) 33:5–10.
   Web of Science ®Google Scholar
• EMLEN W, NIEBUR J, FLANDERS G, RUTLEDGE J: Measure-ment of serum hyaluronan in patients with rheumaotid arthritis: correlation with disease activity. J. Rheumatol. (1996) 23:974–978.
   PubMedGoogle Scholar
• WOESSNER JF: Serum hyaluronan: a status report. Ar-thritis Rheum. (1991) 34:927–930.
   PubMed Web of Science ®Google Scholar
• FORSLIND K, EBERHARDT K, JONSSON A, SAXNE T: In-creased serum concentrations of cartilage oligomeric protein. Prognostic marker in early rheumaotid arthri-tis. Br. J. Rheumatol. (1992) 31:593–598.
   Google Scholar
• SAXNE T, ZUNINO L, HEINEGARD D: Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum. (1995) 38:82–90.
   PubMed Web of Science ®Google Scholar
• DUCY P, DESBOIS C, BOYCE B et al.: Increased boneformation in osteocalcin-deficient mice. Nature (1996) 382448–452.
   Google Scholar
• WOLHEIM FA: Biochemical markers of joint tissue de-struction in rheumatoid arthritis. Rheumatol. Eur. (1995) 2(Suppl.):173–175.
   Google Scholar
• MELKKO J, MSEMI S, RISTELI L, RISTELI J: Radioimmunoas-say of the carboxyterminal propeptide of human type-I procollagen. Clin. Chem. (1990) 36:1328–1332.
   PubMed Web of Science ®Google Scholar
• DELMAS PD, GINEYTS E, BERTHOLIN A, GARNERO P, MARCHARD F: Immunoassays of pyridinoline crosslink excretion in normal adults and in Paget's disease. J. Bone Miner Res. (1993) 8:643–648.
   PubMed Web of Science ®Google Scholar
• ASTBURY C, BIRD HA, MCLAREN AM, ROBINS SP: Urinaryexcretion of pyridinium crosslinks of collagen corre-lated with joint damage in arthritis. J. Rheumatol. (1994) 33:11–15.
   Google Scholar
• MACDONALD AG, MCHENRY P, ROBINS SP, REID DM: Relationship of urinary pyridinium crosslinks to dis-ease extent and activity in arthritis. J. Rheumatol. (1994) 33:16–19.
   Web of Science ®Google Scholar
• AXFORD JS, MACKENZIE L, LYDYARD PM et al.: ReducedB-cell galactosykransferase activity in rheumatoid ar-thritis. Lancet (1987) ii:1286–1288.
   Google Scholar
• LACKI JK, PORAWSKA W, MACKIEWICZ U, MACICIEWICZ S, MULLER W: Changes in agalactosyl IgG levels correlate with radiological progression in early rheumatoid ar-thritis. J. Rheumatol. (1996) 28:265–269.
   Google Scholar
• AREND WP, DAYER J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS, ALVARO-GARCIA JM, MAXI R: Quantitative analysis of cytokine gene expression in rheumatoid arrthritis. J. Immunol. (1990) 144:3347–3353.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS, ZVAIF1ER NJ: How important are T-cells in chronic rheumatoid synovitis? Arthritis Rheum. (1990) 33:768-773.
   Google Scholar
• TETrA C, CAMUSSI G, MODENA V, DIVITOTORIO C, BAGLIONI c: Tumor necrosis factor in serum and synovial fluids and patients with active and severe rheumatoid arthritis. Ann. Rheum. Dis. (1990) 49:665–667.
   PubMed Web of Science ®Google Scholar
• KAHLE P, SAAL JG, SCHAUDT K et al.: Determination ofcytokines in synovial fluids: correlation with diagnosis and histomorpholgical characteristics of synovial tis-sue. Ann. Rheum. Dis. (1992) 51:731–734.
   PubMed Web of Science ®Google Scholar
• CHU CQ, FIELD M, FELDMAN M, MAINI RN: Localizationof tumor necrosis factor a in synovial tissue and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34:1125–1132.
   PubMed Web of Science ®Google Scholar
• EASTGATE JA, SYMONS JA, WOOD NC et al.: Correlationof plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet (1988) 1E706–709.
   Google Scholar
• KIRKHAM BW, NAVARRO FJ, CORKILL MM, GIBSON T,PANAYI GS: Changes in interleukin 1 beta expression In rheumatoid synovial membrane after treatment with gold and glucocorticoid. Clin. Rheumatol. (1990) 9:118–119.
   Google Scholar
• BROZIK M, ROSZTOCZY I, MERETEY K et al.: Interleukin6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid fac-tor and systemic acute phase protein production. J. Rheumatol. (1991) 19:63–68.
   Web of Science ®Google Scholar
• DASGUPTA B, CORKILL,KIRHAM B, GIBSON T, PANAYI G:Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol. (1992) 19:22–25.
   PubMed Web of Science ®Google Scholar
• WANG P, WU P, SIEGEL MI, EGAN RW, BILIAH MM: Interleuldn (IL)-10 inhibits nuclear factor KB (NFicB) activation in human monocytes. J. Immunol. (1995) 270:9558–9563.
   Google Scholar
• MIOSSEC P, NAVILIAT M, D'ANGEAC AD, SANY J, BANCHERAU J: Low levels of interleukin-4 and high levels of transforming growth factor 13 in rheumatoid synovitis. Arthritis Rheum. (1990) 33:1180–1187.
   PubMed Web of Science ®Google Scholar
• ISOMAKI P, LUUKKKAINEN R, SAARIO R, TOIVANEN P, PUNNONEN J: Interleukin-10 functions as an antiinflam-matory cytokine in rheumatoid synovium. Arthritis Rheum. (1996) 39:386–395.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS, BOYLE D, YU C et al.: Synovial fluidinterleukin-1 receptor antagonist and interleukin-1 bal-ance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–652.
   PubMed Web of Science ®Google Scholar
• UN MKS, FAREWELL V, VADAS P et al.: Secretory phos-pholipase A2 as an index of disease activity in rheuma-toid arthritis - prospective double-blind study of 212 patients. J. Rheumatot (1996) 23:1162–1166.
   PubMed Web of Science ®Google Scholar
• STEFANOVIC-RACIC M, STADLER J, EVANS CH: Nitric ox-ide and arthritis. Arthritis Rheum. (1993) 36:1036–1044.
   PubMed Web of Science ®Google Scholar
• FARRELL AJ, BLAKE DR, PALMER RMJ, MONCADA S: In-creased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. (1992) 51:1219–1222.
   PubMed Web of Science ®Google Scholar
• JACOB T, MORRELL M, MANZI S, VERDILE V, SIMMONS EL: Elevated nitrates in inflammatory joint disease: nitric oxide arthritis. Arthritis Rheum. (1992) 35\(Suppl. 5):R9.
   Google Scholar
• KAUR H, HALIIWELL B: Evidence for nitric oxide-medi-ated oxidative damage in chronic inflanunation. Nitro-tyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett. (1994) 350:9–12.
   Google Scholar
• STICHTENOTH DO, FAULER J, ZEIDLER H, FROLICH JC: Urrinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by predrilsolone. Ann. Rheum. Dig. (1995) 54:820–824.
   PubMed Web of Science ®Google Scholar
• GRABOWSKI PS, ENGLAND AJ, DYKHUIZEN R et al.: Ele-vated nitric oxide production in rheumatoid arthritis - detection using the fasting urinary nitrate creatinine ratio. Arthritis Rheum. (1996) 39:643–647.
   PubMed Web of Science ®Google Scholar
• HASTY K, REIFE RA, KANG AH, STUART JM: The role ofstromelysin in the cartilage destruction that accompa-nies inflammatory arthritis. Arthritis Rheum. (1990) 33:388–397.
   PubMed Web of Science ®Google Scholar
• WOESSNER JF: Matrix metalloproteinases and their in-hibitors in connective tissue remodelling. FASEB (1991) 5:2145–2154.
   PubMed Web of Science ®Google Scholar
• GRUBER BL, SORBI D, FRENCH DL et al.: Markedly ele-vated serum MM-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. din. Immunol. Immunopathol. (1996) 78:161–171.
   PubMedGoogle Scholar
• YOSHIHARA Y, OBATA KI, FUJIMOTO N et al.: Increased levels of stromelysin-1 and tissue inhibitor of metallo-proteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum. (1996) 38:969–975.
   Web of Science ®Google Scholar
• FIRESTEIN GS, PAINE MM: Stromelysist and tissue inhibi-tor of metalloproteinase gene expression in rheuma-toid arthritis synovium. Am. J. Pathol. (1992) 140:1309–1314.
   PubMed Web of Science ®Google Scholar
• PEEL NFA, SPITTLEHOUSE AJ, BAN DE, EASTEU R: Bonemineral density of the hand in rheumatoid arthritis. Arthritis. Rheum. (1994) 37:983–991.
   PubMed Web of Science ®Google Scholar
• WATERTON JC: The role of measurement and quantifi-cation in magnetic resonance assessment of arthritis. Acta Pharm. (1993) 43:287–290.
   Google Scholar
• FOLEY ND, STACK JP, RYAN M et al.: Magnetic resonanceImaging in the assessment of rheumatoid arthritis - a comparison with plain film radiographs. Br.J. Rheuma-tot (1991) 30:101–106.
   PubMed Web of Science ®Google Scholar
• POLEKSIC L, ZDRAVKOVIC DM, JABLANOVIC D et al.: Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography. Skeletal Radiol. (1993) 22:577–580.
   PubMed Web of Science ®Google Scholar
• OSTERGAARD M, STOLTENBERG M, GIDEON P et al.: Changes in synovial membrane and joint efffusion volumes after intraarticuular methylprednisolone. Quantitative assessment of inflammatory and destruc-tive changes in arthritis by MRL J. Rheumatot (1996) 23:1151–1161.
   Google Scholar